Oxford BioDynamics has announced Professor Iain McInnes will join its scientific advisory board.
Professor McInnes is director of the Institute of Infection, Immunity and Inflammation at Glasgow University and internationally recognised for his research into arthritis.
He will use his expertise to help further develop OBD’S EpiSwitch technology, which analyses biomarkers to help pharma and biotech companies identify how patients will react to specific drugs.
Oxford BioDynamics, which has its head office in Beaumont Street and labs at Oxford Business Park, was spun-out of Oxford University in 2007.
It floated on AIM in 2016 and received the Queen’s Award for Innovation in April this year.
Professor McInnes, who was awarded a CBE for services to medicine last December, has collaborated with Oxford BioDynamics on research projects during the past five years.
OBD chief executive Christian Hoyer Millar said: “Iain is an eminent professor and an expert in inflammatory disease processes, a core focus for us.
“His knowledge and experience will be hugely beneficial, as we further collaborate with leading pharma, biotech and research institutions.”
Professor McInnes added: “I have known OBD for many years now and am extremely impressed with the predictive power of EpiSwitch to identify patients with rheumatoid arthritis who would not respond adequately to methotrexate, the anchor drug used in this disease.”
Oxford biotech company e-therapeutics is offering its powerful network-biology-and AI-based drug discovery platform to help tackle the Covid-19 pandemic.
The OxVent ventilator for Covid-19 patients, developed in just two weeks in March by engineers and medics in Oxford and London, is being tested for safety and usability at the Smith+Nephew medical manufacturing facility in Hull.
Researchers in Oxford and Zurich have used artificial intelligence (AI) and computer visualisation technology to detect changes in colon cancer cells that could be connected to the ‘expression’ of some smell-sensing genes.
Matthew Cobb’s book charts the history of efforts to understand the brain and brings us up to date with the latest developments in neuroscience.